---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023412"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:39:33.243833+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q2 revenue $8.5M, net loss $5.1M; arimoclomol NDA resubmission on track for Q4 2023

## Summary
- Net revenue $8.5M in Q2 2023 vs $1.3M YoY, driven by $5M AZSTARYS milestone and royalties.
- Net loss $5.1M ($0.15/share) vs $24.0M ($0.70) in Q2 2022; prior year included $17.7M acquired IPR&D charge.
- Cash $87.4M as of June 30, 2023, supporting operations into 2026; $5M milestone received after quarter-end.
- Pre-submission meeting with FDA for arimoclomol NDA completed; resubmission expected Q4 2023.
- Phase 2 KP1077 IH trial enrolling; interim data expected Q3 2023; topline data H1 2024; narcolepsy IND opened.

## SEC filing metadata
- accession: 0001437749-23-023412
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923023412/0001437749-23-023412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923023412/zvra20230519_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023412
- JSON: https://secwatch.observer/filing/0001437749-23-023412.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023412.txt

## Key facts
- Earnings Releases
  ZEVRA THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: revenue $8.5 million, net income ($5.1) million, EPS ($0.15).
  - Period: second quarter ended June 30, 2023
  - Revenue: $8.5 million
  - Net income: ($5.1) million
  - EPS: ($0.15)
  - Result: reported results
  source text: Net revenue for Q2 2023 was $8.5 million compared to Q2 2022 net revenue of $1.3 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774923023412/0001437749-23-023412-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.